Adjustments to Financial Statements
Paying user area
Try for free
Cytokinetics Inc. pages available for free this week:
- Balance Sheet: Assets
- Analysis of Profitability Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Selected Financial Data since 2005
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cytokinetics Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Adjustments to Total Assets
Cytokinetics Inc., adjusted total assets
US$ in thousands
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »
2 Noncurrent deferred tax assets, net. See details »
Adjustments to Total Liabilities
Cytokinetics Inc., adjusted total liabilities
US$ in thousands
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Operating lease liability (before adoption of FASB Topic 842). See details »
2 Noncurrent deferred tax liabilities. See details »
Adjustments to Stockholders’ Equity
Cytokinetics Inc., adjusted stockholders’ equity (deficit)
US$ in thousands
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Net deferred tax assets (liabilities). See details »
Adjustments to Capitalization Table
Cytokinetics Inc., adjusted capitalization table
US$ in thousands
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Operating lease liability (before adoption of FASB Topic 842). See details »
2 Short-term operating lease liabilities. See details »
3 Long-term operating lease liabilities. See details »
4 Net deferred tax assets (liabilities). See details »
Adjustments to Revenues
Cytokinetics Inc., adjusted revenues
US$ in thousands
| 12 months ended: | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
|---|---|---|---|---|---|---|
| As Reported | ||||||
| Revenues | ||||||
| Adjustment | ||||||
| Add: Increase (decrease) in deferred revenue | ||||||
| After Adjustment | ||||||
| Adjusted revenues | ||||||
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Adjustments to Reported Income
Cytokinetics Inc., adjusted net loss
US$ in thousands
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 Deferred income tax expense (benefit). See details »